JenYii的个人主页 - 老虎社区

JenYii

JenYii

暂无个人介绍

IP属地：未知

320关注

12粉丝

0主题

0勋章

2021-04-20

Comment and like, pls.

抱歉，原内容已删除

2021-08-09

Like & comment, please………👆🏻🙏🏻

BioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid<blockquote>BioNTech 股票因盈利大幅上涨；公司着眼于新冠疫情之外</blockquote>

2021-08-01

Like & comment, please………….👆🏻🙏🏻

抱歉，原内容已删除

2021-07-31

Please like ……….………………….👆🏻🙏🏻

抱歉，原内容已删除

2021-04-24

Like and comment pls

Why AMD Stock Popped After Intel's Earnings Beat<blockquote>为什么英特尔盈利超出预期后 AMD 股价飙升</blockquote>

2021-08-08

Like & comment, please………👆🏻🙏🏻

SEC Moves First DeFi Unregistered Securities Lawsuit<blockquote>SEC 提起首例 DeFi 未注册证券诉讼</blockquote>

2021-08-01

Please like and comment 🙏🏻

抱歉，原内容已删除

2021-04-15

It’s temporary 🦾

抱歉，原内容已删除

2021-12-06

Ok

Why Moderna Is the Biggest Winner From COVID Boosters So Far<blockquote>为什么 Moderna 是迄今为止新冠疫苗的最大赢家</blockquote>

2021-04-05

[得意] [财迷] [笑哭]

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3559395309338899","uuid":"3559395309338899","gmtCreate":1596349342614,"gmtModify":1612695532145,"name":"JenYii","pinyin":"jenyii","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":12,"headSize":320,"tweetSize":38,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.42%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.07","exceedPercentage":"80.81%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":608534193,"gmtCreate":1638756985400,"gmtModify":1638756985492,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/608534193","repostId":"1125593879","repostType":4,"repost":{"id":"1125593879","kind":"news","pubTimestamp":1638756575,"share":"https://www.laohunote.com/m/news/1125593879?lang=zh_CN&edition=full","pubTime":"2021-12-06 10:09","market":"us","language":"en","title":"Why Moderna Is the Biggest Winner From COVID Boosters So Far<blockquote>为什么 Moderna 是迄今为止新冠疫苗的最大赢家</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125593879","media":"Motley Fool","summary":"It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authoriz","content":"<p>It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authorized boosters for the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) for certain groups. Around two and half months ago, the agency granted authorizations for boosters for Moderna's (NASDAQ:MRNA) and Johnson &amp; Johnson's (NYSE:JNJ) vaccines, with limitations for which individuals could receive the Moderna booster.</p><p><blockquote>距离美国已经过去了大约三个半月。美国食品药品监督管理局 (FDA) 批准辉瑞 (NYSE:PFE) 和 BioNTech (NASDAQ:BNTX) 为某些群体开发的 COVID-19 疫苗加强剂。大约两个半月前，该机构批准了 Moderna（纳斯达克股票代码：MRNA）和强生公司（纽约证券交易所股票代码：JNJ）疫苗的加强剂，但对个人可以接受 Moderna 加强剂的数量有限制。</blockquote></p><p> A little over two weeks ago, the FDA broadened its Emergency Use Authorization for the Pfizer-BioNTech and Moderna boosters to include all adults ages 18 and older. Overall, close to 42 million Americans have received booster shots.</p><p><blockquote>两个多星期前，FDA扩大了辉瑞-BioNTech和Moderna加强剂的紧急使用授权，将所有18岁及以上的成年人包括在内。总体而言，近 4200 万美国人接受了加强注射。</blockquote></p><p> Which vaccine maker is winning the battle of the boosters so far? It's still early, but Moderna appears to be ahead in several respects</p><p><blockquote>到目前为止，哪家疫苗制造商正在赢得加强剂之战？现在还为时尚早，但 Moderna 似乎在几个方面处于领先地位</blockquote></p><p> <b>Analyzing the data</b></p><p><blockquote><b>分析数据</b></blockquote></p><p> More booster doses of the Pfizer-BioNTech vaccine have been given than have been administered for the Moderna and J&amp;J boosters. Pfizer and BioNTech are clearly in the lead on this front.</p><p><blockquote>辉瑞-BioNTech疫苗的加强剂量超过了Moderna和J&amp;J加强剂。辉瑞和BioNTech显然在这方面处于领先地位。</blockquote></p><p> You'd expect that more people would have received the Pfizer-BioNTech booster. It's been available for many Americans (including those ages 65 and older) for a month longer than the other two vaccine types.</p><p><blockquote>你会期望更多的人会接受辉瑞-BioNTech加强剂。许多美国人（包括65岁及以上的人）的接种时间比其他两种疫苗多一个月。</blockquote></p><p> Also, many more individuals received the Pfizer-BioNTech vaccine initially than received the other two vaccines. A lot of those people chose to receive the booster of the same vaccine that they received for their primary series. The chart below shows how the different vaccines stack up against each other based on the fully vaccinated numbers.</p><p><blockquote>此外，最初接受辉瑞-BioNTech疫苗的人比接受其他两种疫苗的人多得多。这些人中的许多人选择接受与他们在主要系列中接受的相同疫苗的加强。下图显示了基于完全接种疫苗的数量，不同疫苗是如何相互对抗的。</blockquote></p><p> So why do I maintain that Moderna is the biggest winner with boosters so far and not Pfizer or BioNTech? There are three reasons.</p><p><blockquote>那么，为什么我坚持认为Moderna是迄今为止最大的助推器赢家，而不是辉瑞或BioNTech呢？原因有三个。</blockquote></p><p> First, from a financial standpoint, Moderna's 18 million booster doses made it more money than Pfizer or BioNTech made from their 23.3 million or so booster doses. Moderna doesn't have to split its profits as Pfizer and BioNTech do.</p><p><blockquote>首先，从财务角度来看，Moderna 的 1800 万剂加强剂比辉瑞或 BioNTech 的 2330 万剂左右加强剂赚的钱还要多。Moderna 不必像辉瑞和 BioNTech 那样分配利润。</blockquote></p><p> Second, Moderna is gaining more traction with boosters than Pfizer-BioNTech or J&amp;J are. A little over 25% of the number of fully vaccinated individuals receiving the primary series of the Moderna vaccine have received Moderna boosters. The ratio is 21.3% for Pfizer-BioNTech.</p><p><blockquote>其次，与辉瑞-BioNTech或强生相比，Moderna在加强剂方面获得了更多的牵引力。接受Moderna疫苗初级系列的完全接种疫苗的个体中，略高于25%的人接受了Moderna加强剂。辉瑞-BioNTech的这一比例为21.3%。</blockquote></p><p> Third, with the FDA allowing mix-and-match boosters, more people appear to be switching from another vaccine to Moderna than they are to any other vaccine type. For those who initially received the J&amp;J vaccine, 42.5% so far have gone with the Moderna booster versus 31.2% for a Pfizer-BioNTech booster and only 26.2% for a J&amp;J booster.</p><p><blockquote>第三，随着FDA允许混合搭配加强剂，从另一种疫苗转向Moderna的人似乎比任何其他疫苗类型的人都多。对于那些最初接受J&amp;J疫苗的人来说，到目前为止，42.5%的人使用了Moderna加强剂，而31.2%的人使用了辉瑞-BioNTech加强剂，只有26.2%的人使用了J&amp;J加强剂。</blockquote></p><p> <b>Why is Moderna winning?</b></p><p><blockquote><b>为什么Moderna会赢？</b></blockquote></p><p> We don't know for sure why Moderna seems to be gaining momentum. However, I have a theory for why it could be happening.</p><p><blockquote>我们不确定为什么 Moderna 似乎势头强劲。然而，我有一个理论来解释为什么会发生这种情况。</blockquote></p><p> My hunch is that many Americans have heard that Moderna's efficacy against the delta variant is higher than the efficacy of the Pfizer-BioNTech and Johnson &amp; Johnson vaccines. The initial efficacy of the single-shot J&amp;J vaccine was well below its two messenger RNA vaccine rivals. And the efficacy of the Pfizer-BioNTech vaccine appears to have waned more than the Moderna vaccine has with the rise of the delta variant.</p><p><blockquote>我的预感是，许多美国人都听说过 Moderna 对德尔塔变异毒株的效力高于辉瑞-BioNTech 和强生疫苗的效力。强生单针疫苗的初始效力远低于其两种信使RNA疫苗竞争对手。随着德尔塔变异毒株的上升，辉瑞-BioNTech疫苗的效力似乎比Moderna疫苗减弱得多。</blockquote></p><p> I suspect that preliminary data showing that a mix-and-match combination of the Pfizer-BioNTech primary series and a Moderna booster provides a higher efficacy could also be making a difference to some extent. Singapore's minister of health even recently recommended that citizens in the country who initially received the Pfizer-BioNTech vaccine get the Moderna booster.</p><p><blockquote>我怀疑，初步数据显示辉瑞-BioNTech初级系列和Moderna加强剂的混合搭配组合提供了更高的功效，这也可能在某种程度上产生影响。新加坡卫生部长最近甚至建议该国最初接种辉瑞-BioNTech疫苗的公民接种Moderna加强剂。</blockquote></p><p> <b>What really matters</b></p><p><blockquote><b>真正重要的是什么</b></blockquote></p><p> Don't expect Moderna's relative outperformance in boosters to do much for the vaccine stock. Many investors aren't paying attention to the data. And the U.S. has already purchased enough doses from Moderna to meet the demand, including boosters.</p><p><blockquote>不要指望 Moderna 在加强剂方面的相对优异表现会对疫苗库存产生太大影响。许多投资者并没有关注这些数据。美国已经从 Moderna 购买了足够的剂量来满足需求，包括加强剂。</blockquote></p><p> What really matters for Moderna is how strong the longer-term demand will be for its COVID-19 vaccine. The company's efforts fighting the new omicron variant could play a key role in shaping that demand. But the most important factors will be whether or not annual vaccines are required to prevent COVID-19 and, if so, what price Moderna will be able to charge.</p><p><blockquote>对 Moderna 来说真正重要的是对其 COVID-19 疫苗的长期需求有多强劲。该公司对抗新奥密克戎变种的努力可能会在塑造这一需求方面发挥关键作用。但最重要的因素将是是否需要每年接种疫苗来预防 COVID-19，如果是，Moderna 将能够收取什么价格。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Is the Biggest Winner From COVID Boosters So Far<blockquote>为什么 Moderna 是迄今为止新冠疫苗的最大赢家</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Is the Biggest Winner From COVID Boosters So Far<blockquote>为什么 Moderna 是迄今为止新冠疫苗的最大赢家</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-12-06 10:09</span>\n</p>\n</h4>\n</header>\n<article>\n<p>It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authorized boosters for the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) for certain groups. Around two and half months ago, the agency granted authorizations for boosters for Moderna's (NASDAQ:MRNA) and Johnson &amp; Johnson's (NYSE:JNJ) vaccines, with limitations for which individuals could receive the Moderna booster.</p><p><blockquote>距离美国已经过去了大约三个半月。美国食品药品监督管理局 (FDA) 批准辉瑞 (NYSE:PFE) 和 BioNTech (NASDAQ:BNTX) 为某些群体开发的 COVID-19 疫苗加强剂。大约两个半月前，该机构批准了 Moderna（纳斯达克股票代码：MRNA）和强生公司（纽约证券交易所股票代码：JNJ）疫苗的加强剂，但对个人可以接受 Moderna 加强剂的数量有限制。</blockquote></p><p> A little over two weeks ago, the FDA broadened its Emergency Use Authorization for the Pfizer-BioNTech and Moderna boosters to include all adults ages 18 and older. Overall, close to 42 million Americans have received booster shots.</p><p><blockquote>两个多星期前，FDA扩大了辉瑞-BioNTech和Moderna加强剂的紧急使用授权，将所有18岁及以上的成年人包括在内。总体而言，近 4200 万美国人接受了加强注射。</blockquote></p><p> Which vaccine maker is winning the battle of the boosters so far? It's still early, but Moderna appears to be ahead in several respects</p><p><blockquote>到目前为止，哪家疫苗制造商正在赢得加强剂之战？现在还为时尚早，但 Moderna 似乎在几个方面处于领先地位</blockquote></p><p> <b>Analyzing the data</b></p><p><blockquote><b>分析数据</b></blockquote></p><p> More booster doses of the Pfizer-BioNTech vaccine have been given than have been administered for the Moderna and J&amp;J boosters. Pfizer and BioNTech are clearly in the lead on this front.</p><p><blockquote>辉瑞-BioNTech疫苗的加强剂量超过了Moderna和J&amp;J加强剂。辉瑞和BioNTech显然在这方面处于领先地位。</blockquote></p><p> You'd expect that more people would have received the Pfizer-BioNTech booster. It's been available for many Americans (including those ages 65 and older) for a month longer than the other two vaccine types.</p><p><blockquote>你会期望更多的人会接受辉瑞-BioNTech加强剂。许多美国人（包括65岁及以上的人）的接种时间比其他两种疫苗多一个月。</blockquote></p><p> Also, many more individuals received the Pfizer-BioNTech vaccine initially than received the other two vaccines. A lot of those people chose to receive the booster of the same vaccine that they received for their primary series. The chart below shows how the different vaccines stack up against each other based on the fully vaccinated numbers.</p><p><blockquote>此外，最初接受辉瑞-BioNTech疫苗的人比接受其他两种疫苗的人多得多。这些人中的许多人选择接受与他们在主要系列中接受的相同疫苗的加强。下图显示了基于完全接种疫苗的数量，不同疫苗是如何相互对抗的。</blockquote></p><p> So why do I maintain that Moderna is the biggest winner with boosters so far and not Pfizer or BioNTech? There are three reasons.</p><p><blockquote>那么，为什么我坚持认为Moderna是迄今为止最大的助推器赢家，而不是辉瑞或BioNTech呢？原因有三个。</blockquote></p><p> First, from a financial standpoint, Moderna's 18 million booster doses made it more money than Pfizer or BioNTech made from their 23.3 million or so booster doses. Moderna doesn't have to split its profits as Pfizer and BioNTech do.</p><p><blockquote>首先，从财务角度来看，Moderna 的 1800 万剂加强剂比辉瑞或 BioNTech 的 2330 万剂左右加强剂赚的钱还要多。Moderna 不必像辉瑞和 BioNTech 那样分配利润。</blockquote></p><p> Second, Moderna is gaining more traction with boosters than Pfizer-BioNTech or J&amp;J are. A little over 25% of the number of fully vaccinated individuals receiving the primary series of the Moderna vaccine have received Moderna boosters. The ratio is 21.3% for Pfizer-BioNTech.</p><p><blockquote>其次，与辉瑞-BioNTech或强生相比，Moderna在加强剂方面获得了更多的牵引力。接受Moderna疫苗初级系列的完全接种疫苗的个体中，略高于25%的人接受了Moderna加强剂。辉瑞-BioNTech的这一比例为21.3%。</blockquote></p><p> Third, with the FDA allowing mix-and-match boosters, more people appear to be switching from another vaccine to Moderna than they are to any other vaccine type. For those who initially received the J&amp;J vaccine, 42.5% so far have gone with the Moderna booster versus 31.2% for a Pfizer-BioNTech booster and only 26.2% for a J&amp;J booster.</p><p><blockquote>第三，随着FDA允许混合搭配加强剂，从另一种疫苗转向Moderna的人似乎比任何其他疫苗类型的人都多。对于那些最初接受J&amp;J疫苗的人来说，到目前为止，42.5%的人使用了Moderna加强剂，而31.2%的人使用了辉瑞-BioNTech加强剂，只有26.2%的人使用了J&amp;J加强剂。</blockquote></p><p> <b>Why is Moderna winning?</b></p><p><blockquote><b>为什么Moderna会赢？</b></blockquote></p><p> We don't know for sure why Moderna seems to be gaining momentum. However, I have a theory for why it could be happening.</p><p><blockquote>我们不确定为什么 Moderna 似乎势头强劲。然而，我有一个理论来解释为什么会发生这种情况。</blockquote></p><p> My hunch is that many Americans have heard that Moderna's efficacy against the delta variant is higher than the efficacy of the Pfizer-BioNTech and Johnson &amp; Johnson vaccines. The initial efficacy of the single-shot J&amp;J vaccine was well below its two messenger RNA vaccine rivals. And the efficacy of the Pfizer-BioNTech vaccine appears to have waned more than the Moderna vaccine has with the rise of the delta variant.</p><p><blockquote>我的预感是，许多美国人都听说过 Moderna 对德尔塔变异毒株的效力高于辉瑞-BioNTech 和强生疫苗的效力。强生单针疫苗的初始效力远低于其两种信使RNA疫苗竞争对手。随着德尔塔变异毒株的上升，辉瑞-BioNTech疫苗的效力似乎比Moderna疫苗减弱得多。</blockquote></p><p> I suspect that preliminary data showing that a mix-and-match combination of the Pfizer-BioNTech primary series and a Moderna booster provides a higher efficacy could also be making a difference to some extent. Singapore's minister of health even recently recommended that citizens in the country who initially received the Pfizer-BioNTech vaccine get the Moderna booster.</p><p><blockquote>我怀疑，初步数据显示辉瑞-BioNTech初级系列和Moderna加强剂的混合搭配组合提供了更高的功效，这也可能在某种程度上产生影响。新加坡卫生部长最近甚至建议该国最初接种辉瑞-BioNTech疫苗的公民接种Moderna加强剂。</blockquote></p><p> <b>What really matters</b></p><p><blockquote><b>真正重要的是什么</b></blockquote></p><p> Don't expect Moderna's relative outperformance in boosters to do much for the vaccine stock. Many investors aren't paying attention to the data. And the U.S. has already purchased enough doses from Moderna to meet the demand, including boosters.</p><p><blockquote>不要指望 Moderna 在加强剂方面的相对优异表现会对疫苗库存产生太大影响。许多投资者并没有关注这些数据。美国已经从 Moderna 购买了足够的剂量来满足需求，包括加强剂。</blockquote></p><p> What really matters for Moderna is how strong the longer-term demand will be for its COVID-19 vaccine. The company's efforts fighting the new omicron variant could play a key role in shaping that demand. But the most important factors will be whether or not annual vaccines are required to prevent COVID-19 and, if so, what price Moderna will be able to charge.</p><p><blockquote>对 Moderna 来说真正重要的是对其 COVID-19 疫苗的长期需求有多强劲。该公司对抗新奥密克戎变种的努力可能会在塑造这一需求方面发挥关键作用。但最重要的因素将是是否需要每年接种疫苗来预防 COVID-19，如果是，Moderna 将能够收取什么价格。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/12/05/why-moderna-is-the-biggest-winner-from-covid-boost/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/12/05/why-moderna-is-the-biggest-winner-from-covid-boost/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125593879","content_text":"It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authorized boosters for the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) for certain groups. Around two and half months ago, the agency granted authorizations for boosters for Moderna's (NASDAQ:MRNA) and Johnson & Johnson's (NYSE:JNJ) vaccines, with limitations for which individuals could receive the Moderna booster.\n\nA little over two weeks ago, the FDA broadened its Emergency Use Authorization for the Pfizer-BioNTech and Moderna boosters to include all adults ages 18 and older. Overall, close to 42 million Americans have received booster shots.\n\nWhich vaccine maker is winning the battle of the boosters so far? It's still early, but Moderna appears to be ahead in several respects\nAnalyzing the data\nMore booster doses of the Pfizer-BioNTech vaccine have been given than have been administered for the Moderna and J&J boosters. Pfizer and BioNTech are clearly in the lead on this front.\n\nYou'd expect that more people would have received the Pfizer-BioNTech booster. It's been available for many Americans (including those ages 65 and older) for a month longer than the other two vaccine types.\n\nAlso, many more individuals received the Pfizer-BioNTech vaccine initially than received the other two vaccines. A lot of those people chose to receive the booster of the same vaccine that they received for their primary series. The chart below shows how the different vaccines stack up against each other based on the fully vaccinated numbers.\n\nSo why do I maintain that Moderna is the biggest winner with boosters so far and not Pfizer or BioNTech? There are three reasons.\n\nFirst, from a financial standpoint, Moderna's 18 million booster doses made it more money than Pfizer or BioNTech made from their 23.3 million or so booster doses. Moderna doesn't have to split its profits as Pfizer and BioNTech do.\n\nSecond, Moderna is gaining more traction with boosters than Pfizer-BioNTech or J&J are. A little over 25% of the number of fully vaccinated individuals receiving the primary series of the Moderna vaccine have received Moderna boosters. The ratio is 21.3% for Pfizer-BioNTech.\n\nThird, with the FDA allowing mix-and-match boosters, more people appear to be switching from another vaccine to Moderna than they are to any other vaccine type. For those who initially received the J&J vaccine, 42.5% so far have gone with the Moderna booster versus 31.2% for a Pfizer-BioNTech booster and only 26.2% for a J&J booster.\n\nWhy is Moderna winning?\nWe don't know for sure why Moderna seems to be gaining momentum. However, I have a theory for why it could be happening.\n\nMy hunch is that many Americans have heard that Moderna's efficacy against the delta variant is higher than the efficacy of the Pfizer-BioNTech and Johnson & Johnson vaccines. The initial efficacy of the single-shot J&J vaccine was well below its two messenger RNA vaccine rivals. And the efficacy of the Pfizer-BioNTech vaccine appears to have waned more than the Moderna vaccine has with the rise of the delta variant.\n\nI suspect that preliminary data showing that a mix-and-match combination of the Pfizer-BioNTech primary series and a Moderna booster provides a higher efficacy could also be making a difference to some extent. Singapore's minister of health even recently recommended that citizens in the country who initially received the Pfizer-BioNTech vaccine get the Moderna booster.\n\nWhat really matters\nDon't expect Moderna's relative outperformance in boosters to do much for the vaccine stock. Many investors aren't paying attention to the data. And the U.S. has already purchased enough doses from Moderna to meet the demand, including boosters.\n\nWhat really matters for Moderna is how strong the longer-term demand will be for its COVID-19 vaccine. The company's efforts fighting the new omicron variant could play a key role in shaping that demand. But the most important factors will be whether or not annual vaccines are required to prevent COVID-19 and, if so, what price Moderna will be able to charge.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":3963,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":898497158,"gmtCreate":1628516416674,"gmtModify":1631889789540,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"title":"","htmlText":"Like &amp; comment, please………👆🏻🙏🏻","listText":"Like &amp; comment, please………👆🏻🙏🏻","text":"Like & comment, please………👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":13,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/898497158","repostId":"2158238441","repostType":4,"repost":{"id":"2158238441","kind":"highlight","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1628514928,"share":"https://www.laohunote.com/m/news/2158238441?lang=zh_CN&edition=full","pubTime":"2021-08-09 21:15","market":"us","language":"en","title":"BioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid<blockquote>BioNTech 股票因盈利大幅上涨；公司着眼于新冠疫情之外</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2158238441","media":"Investors","summary":"BioNTech stock popped on Monday after reporting adjusted profit of $12.67 a share on $6.24 billion in second-quarter sales.","content":"<p>BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.</p><p><blockquote>BioNTech 股价周一大幅上涨，此前这家新冠疫苗制造商公布第二季度销售额为 62.4 亿美元，调整后每股利润为 12.67 美元。</blockquote></p><p> Analysts polled by FactSet expected <b>BioNTech</b> to earn $8.87 per share on $3.83 billion in sales.</p><p><blockquote>FactSet 调查的分析师预计<b>生物技术</b>销售额为 38.3 亿美元，每股收益为 8.87 美元。</blockquote></p><p> In the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.</p><p><blockquote>去年同期，BioNTech 每股亏损 45 美分，收入为 4900 万美元。</blockquote></p><p> BioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the <b>Pfizer</b> partner to earn $33.12 a share on $14.68 billion in sales.</p><p><blockquote>BioNTech 没有提供全年销售和盈利指引。该公司指出，已达成协议，将在 2021 年交付 22 亿剂新冠疫苗，目前正在研发多种抗癌药物。分析师呼吁<b>辉瑞</b>partner 的销售额为 146.8 亿美元，每股收益为 33.12 美元。</blockquote></p><p> In premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.</p><p><blockquote>在今天股市盘前交易中，BioNTech 股价上涨 5%，接近 408.50 点。根据 IBD Digital 的数据，该股的相对强弱评级为 99。就 12 个月的业绩而言，这使得 BioNTech 股票在所有公司中排名前 1%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid<blockquote>BioNTech 股票因盈利大幅上涨；公司着眼于新冠疫情之外</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid<blockquote>BioNTech 股票因盈利大幅上涨；公司着眼于新冠疫情之外</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time smaller\">2021-08-09 21:15</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.</p><p><blockquote>BioNTech 股价周一大幅上涨，此前这家新冠疫苗制造商公布第二季度销售额为 62.4 亿美元，调整后每股利润为 12.67 美元。</blockquote></p><p> Analysts polled by FactSet expected <b>BioNTech</b> to earn $8.87 per share on $3.83 billion in sales.</p><p><blockquote>FactSet 调查的分析师预计<b>生物技术</b>销售额为 38.3 亿美元，每股收益为 8.87 美元。</blockquote></p><p> In the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.</p><p><blockquote>去年同期，BioNTech 每股亏损 45 美分，收入为 4900 万美元。</blockquote></p><p> BioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the <b>Pfizer</b> partner to earn $33.12 a share on $14.68 billion in sales.</p><p><blockquote>BioNTech 没有提供全年销售和盈利指引。该公司指出，已达成协议，将在 2021 年交付 22 亿剂新冠疫苗，目前正在研发多种抗癌药物。分析师呼吁<b>辉瑞</b>partner 的销售额为 146.8 亿美元，每股收益为 33.12 美元。</blockquote></p><p> In premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.</p><p><blockquote>在今天股市盘前交易中，BioNTech 股价上涨 5%，接近 408.50 点。根据 IBD Digital 的数据，该股的相对强弱评级为 99。就 12 个月的业绩而言，这使得 BioNTech 股票在所有公司中排名前 1%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158238441","content_text":"BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.\nAnalysts polled by FactSet expected BioNTech to earn $8.87 per share on $3.83 billion in sales.\nIn the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.\nBioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the Pfizer partner to earn $33.12 a share on $14.68 billion in sales.\nIn premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.","news_type":1,"symbols_score_info":{"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":2756,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891650118,"gmtCreate":1628388100434,"gmtModify":1631889789559,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"title":"","htmlText":"Like &amp; comment, please………👆🏻🙏🏻","listText":"Like &amp; comment, please………👆🏻🙏🏻","text":"Like & comment, please………👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/891650118","repostId":"1180529438","repostType":4,"repost":{"id":"1180529438","kind":"news","pubTimestamp":1628386129,"share":"https://www.laohunote.com/m/news/1180529438?lang=zh_CN&edition=full","pubTime":"2021-08-08 09:28","market":"us","language":"en","title":"SEC Moves First DeFi Unregistered Securities Lawsuit<blockquote>SEC 提起首例 DeFi 未注册证券诉讼</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1180529438","media":"Benzinga","summary":"The United States Securities and Exchange Commission  sued the organization responsible for the development of a decentralized finance  protocol over activities involved with the project for the first time.What Happened: According to a Friday SEC announcement, the agency has sued Cayman Islands-based Blockchain Credit Partners and two of its top executives over allegedly selling unregistered securities through its DeFi Money Market platform from February 2020 to February 2021. The firm purported","content":"<p><div> The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project ...</p><p><blockquote><div>美国证券交易委员会（SEC）就该项目涉及的活动起诉了负责开发去中心化金融（DeFi）协议的组织……</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">网页连接</a></blockquote></p><p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SEC Moves First DeFi Unregistered Securities Lawsuit<blockquote>SEC 提起首例 DeFi 未注册证券诉讼</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSEC Moves First DeFi Unregistered Securities Lawsuit<blockquote>SEC 提起首例 DeFi 未注册证券诉讼</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2021-08-08 09:28</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project ...</p><p><blockquote><div>美国证券交易委员会（SEC）就该项目涉及的活动起诉了负责开发去中心化金融（DeFi）协议的组织……</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">Benzinga</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc."},"source_url":"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180529438","content_text":"The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project for the first time.\nWhat Happened: According to a Friday SEC announcement, the agency has sued Cayman Islands-based Blockchain Credit Partners and two of its top executives over allegedly selling unregistered securities through its DeFi Money Market platform from February 2020 to February 2021. The firm purportedly sold over $30 million worth of two types of tokens that the SEC deemed to be securities that should have been registered as such.\nThe SEC notes that Blockchain Credit Partners founders Gregory Keough and Derek Acree will have to pay fines of $125,000 while the company itself also agreed to pay $12.8 million in disgorgement. The settlement does not indicate an admition or denial the accusations.\nNew Game, Old Rules?\nSEC Enforcement Director Gurbir Grewal explained that \"full and honest disclosure remains the cornerstone of our securities laws — no matter what technologies are used to offer and sell those securities.\" This comment makes it very clear that slapping the DeFi label on a project and hoping to avoid regulation this way works no better than calling it a \"utility token\" prevented falling under the SEC's scrutiny during 2017's initial coin offering craze.\nThe SEC is trying to send the clear rule that the new kind of financial organizations that operate on blockchains have to still play by the old rules that govern traditional finance. At the same time, market onlookers are not sure if the regulator is actually right.\nIn a way, it is a tour de force where the regulator wins every time it has a way to take enforcement action, but these new organizations potentially have a very real way to make enforcement impossible — or at the very least impractical. The only protection against enforcement by the SEC and other regulators is decentralization and the only reason why the SEC was able to act in this case is that a centralized organization such as Blockchain Credit Partners exists.\nWhat's Next:If no company exists and all that there is to a DeFi protocol is a set of smart contracts deployed on a blockchain by a group of anonymous developers scattered around the world there is very little that the SEC can do short of attacking the blockchain itself. This is where the decentralization of the underlying blockchain comes into play: will the regulators for instance be able to force Ethereum's (CRYPTO: ETH) core development team to write an update stopping such a project?\nIf the regulators would actually be able to force the blockchain's developers to write such an update, would node operators and miners or stakers adopt this software or would they refuse to? Such situations will be the real test of the decentralization and reliability of any blockchain that many are waiting to happen. Regulators are seeing power slipping away between their fingers like sand, and they are going to try to grab it.","news_type":1,"symbols_score_info":{"COIN":0.9}},"isVote":1,"tweetType":1,"viewCount":3096,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802510374,"gmtCreate":1627787223898,"gmtModify":1631889789570,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"title":"","htmlText":"Please like and comment 🙏🏻","listText":"Please like and comment 🙏🏻","text":"Please like and comment 🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/802510374","repostId":"1159296868","repostType":4,"isVote":1,"tweetType":1,"viewCount":2760,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802534082,"gmtCreate":1627787044146,"gmtModify":1631889789579,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"title":"","htmlText":"Like &amp; comment, please………….👆🏻🙏🏻","listText":"Like &amp; comment, please………….👆🏻🙏🏻","text":"Like & comment, please………….👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/802534082","repostId":"2155001152","repostType":4,"isVote":1,"tweetType":1,"viewCount":2350,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802379206,"gmtCreate":1627725322505,"gmtModify":1631889789594,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"title":"","htmlText":"Please like ……….………………….👆🏻🙏🏻","listText":"Please like ……….………………….👆🏻🙏🏻","text":"Please like ……….………………….👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/802379206","repostId":"2155001152","repostType":4,"isVote":1,"tweetType":1,"viewCount":3015,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164051645,"gmtCreate":1624162333087,"gmtModify":1631889789608,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"title":"","htmlText":"🙏🏻🙏🏻🙏🏻","listText":"🙏🏻🙏🏻🙏🏻","text":"🙏🏻🙏🏻🙏🏻","images":[{"img":"https://static.tigerbbs.com/d8dd96436bea0b9c92dd95ae16e70361","width":"1125","height":"1074"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164051645","isVote":1,"tweetType":1,"viewCount":2686,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":166010936,"gmtCreate":1623985232225,"gmtModify":1631889789623,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"title":"","htmlText":"Read the safety before flying to the moon 🚀🚀🚀","listText":"Read the safety before flying to the moon 🚀🚀🚀","text":"Read the safety before flying to the moon 🚀🚀🚀","images":[{"img":"https://static.tigerbbs.com/bf7f199d98279f47b434137f93979947","width":"1125","height":"2436"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166010936","isVote":1,"tweetType":1,"viewCount":2330,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":161971406,"gmtCreate":1623902995605,"gmtModify":1631889789642,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"title":"","htmlText":"一分一毫 清清楚楚","listText":"一分一毫 清清楚楚","text":"一分一毫 清清楚楚","images":[{"img":"https://static.tigerbbs.com/2df10f85bb15a2fd54fd84fa66c51782","width":"1125","height":"2436"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161971406","isVote":1,"tweetType":1,"viewCount":3221,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":169061156,"gmtCreate":1623809414075,"gmtModify":1631889789654,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"title":"","htmlText":"Lastly, buy!","listText":"Lastly, buy!","text":"Lastly, buy!","images":[{"img":"https://static.tigerbbs.com/977ef722d3398baaae16beac29e882c8","width":"720","height":"720"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169061156","isVote":1,"tweetType":1,"viewCount":2341,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":185908820,"gmtCreate":1623629234460,"gmtModify":1631889789662,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"title":"","htmlText":"🙏🏻🙏🏻🙏🏻","listText":"🙏🏻🙏🏻🙏🏻","text":"🙏🏻🙏🏻🙏🏻","images":[{"img":"https://static.tigerbbs.com/810dfc226dde7db2efc68b3b69c713e8","width":"1125","height":"1100"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185908820","isVote":1,"tweetType":1,"viewCount":949,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":181470501,"gmtCreate":1623409319803,"gmtModify":1631893519110,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"title":"","htmlText":"🤨🤨🤨","listText":"🤨🤨🤨","text":"🤨🤨🤨","images":[{"img":"https://static.tigerbbs.com/9eef982044c1a06f12729586b864c505","width":"1125","height":"1285"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/181470501","isVote":1,"tweetType":1,"viewCount":906,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":130445533,"gmtCreate":1621563060522,"gmtModify":1631893519123,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"title":"","htmlText":"[Cool]&nbsp;[Cool]&nbsp;[Cool]&nbsp;","listText":"[Cool]&nbsp;[Cool]&nbsp;[Cool]&nbsp;","text":"[Cool] [Cool] [Cool]","images":[{"img":"https://static.tigerbbs.com/2df10f85bb15a2fd54fd84fa66c51782","width":"1125","height":"2436"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/130445533","isVote":1,"tweetType":1,"viewCount":1024,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":194793896,"gmtCreate":1621398562015,"gmtModify":1631893519136,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"title":"","htmlText":"💭💭💭","listText":"💭💭💭","text":"💭💭💭","images":[{"img":"https://static.tigerbbs.com/1b3ccf6b25ac96098455b733bacbd848","width":"1125","height":"1088"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/194793896","isVote":1,"tweetType":1,"viewCount":1119,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":196523017,"gmtCreate":1621077977139,"gmtModify":1631893519150,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"title":"","htmlText":"The choice is yours","listText":"The choice is yours","text":"The choice is yours","images":[{"img":"https://static.tigerbbs.com/9a8a9e98db8fbea1332f77480b0b2c81","width":"1125","height":"2436"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/196523017","isVote":1,"tweetType":1,"viewCount":913,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":198862076,"gmtCreate":1620951484695,"gmtModify":1631893519163,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"title":"","htmlText":"Putting money&nbsp;in a&nbsp;bank or&nbsp;buying the bank shares?","listText":"Putting money&nbsp;in a&nbsp;bank or&nbsp;buying the bank shares?","text":"Putting money in a bank or buying the bank shares?","images":[{"img":"https://static.tigerbbs.com/314825c21655ba8acbb27c7862fd8bac","width":"1125","height":"1070"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/198862076","isVote":1,"tweetType":1,"viewCount":960,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":190589276,"gmtCreate":1620633955095,"gmtModify":1631893519172,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"title":"","htmlText":"Fun fact","listText":"Fun fact","text":"Fun fact","images":[{"img":"https://static.tigerbbs.com/83b46f142a59c6b2396226c8f3fa469f","width":"1125","height":"602"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/190589276","isVote":1,"tweetType":1,"viewCount":638,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":107405123,"gmtCreate":1620526651362,"gmtModify":1631893519186,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"title":"","htmlText":"母亲节快乐 !&nbsp;Happy Mother’s Day !🤎♥️❤️🧡💛💚💙💜🤍","listText":"母亲节快乐 !&nbsp;Happy Mother’s Day !🤎♥️❤️🧡💛💚💙💜🤍","text":"母亲节快乐 ! Happy Mother’s Day !🤎♥️❤️🧡💛💚💙💜🤍","images":[{"img":"https://static.tigerbbs.com/985b573fdaca436c795639ecd2b065c5","width":"1125","height":"1283"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/107405123","isVote":1,"tweetType":1,"viewCount":2705,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":105023023,"gmtCreate":1620260353262,"gmtModify":1631893519201,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"title":"","htmlText":"😎🥸🤓","listText":"😎🥸🤓","text":"😎🥸🤓","images":[{"img":"https://static.tigerbbs.com/df01411b4c036f7e0ec35d5c2817f27d","width":"1125","height":"1260"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/105023023","isVote":1,"tweetType":1,"viewCount":822,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":102897280,"gmtCreate":1620191147440,"gmtModify":1631893519209,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"title":"","htmlText":"Educated&nbsp;them for what they are not learning in school","listText":"Educated&nbsp;them for what they are not learning in school","text":"Educated them for what they are not learning in school","images":[{"img":"https://static.tigerbbs.com/9ffffddc61e04d0a9b36583a41f7c78d","width":"1125","height":"1110"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/102897280","isVote":1,"tweetType":1,"viewCount":534,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":373744064,"gmtCreate":1618887249158,"gmtModify":1634290127183,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"title":"","htmlText":"Comment and like, pls.","listText":"Comment and like, pls.","text":"Comment and like, pls.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/373744064","repostId":"2128689062","repostType":4,"isVote":1,"tweetType":1,"viewCount":663,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898497158,"gmtCreate":1628516416674,"gmtModify":1631889789540,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"title":"","htmlText":"Like &amp; comment, please………👆🏻🙏🏻","listText":"Like &amp; comment, please………👆🏻🙏🏻","text":"Like & comment, please………👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":13,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/898497158","repostId":"2158238441","repostType":4,"repost":{"id":"2158238441","kind":"highlight","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1628514928,"share":"https://www.laohunote.com/m/news/2158238441?lang=zh_CN&edition=full","pubTime":"2021-08-09 21:15","market":"us","language":"en","title":"BioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid<blockquote>BioNTech 股票因盈利大幅上涨；公司着眼于新冠疫情之外</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2158238441","media":"Investors","summary":"BioNTech stock popped on Monday after reporting adjusted profit of $12.67 a share on $6.24 billion in second-quarter sales.","content":"<p>BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.</p><p><blockquote>BioNTech 股价周一大幅上涨，此前这家新冠疫苗制造商公布第二季度销售额为 62.4 亿美元，调整后每股利润为 12.67 美元。</blockquote></p><p> Analysts polled by FactSet expected <b>BioNTech</b> to earn $8.87 per share on $3.83 billion in sales.</p><p><blockquote>FactSet 调查的分析师预计<b>生物技术</b>销售额为 38.3 亿美元，每股收益为 8.87 美元。</blockquote></p><p> In the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.</p><p><blockquote>去年同期，BioNTech 每股亏损 45 美分，收入为 4900 万美元。</blockquote></p><p> BioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the <b>Pfizer</b> partner to earn $33.12 a share on $14.68 billion in sales.</p><p><blockquote>BioNTech 没有提供全年销售和盈利指引。该公司指出，已达成协议，将在 2021 年交付 22 亿剂新冠疫苗，目前正在研发多种抗癌药物。分析师呼吁<b>辉瑞</b>partner 的销售额为 146.8 亿美元，每股收益为 33.12 美元。</blockquote></p><p> In premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.</p><p><blockquote>在今天股市盘前交易中，BioNTech 股价上涨 5%，接近 408.50 点。根据 IBD Digital 的数据，该股的相对强弱评级为 99。就 12 个月的业绩而言，这使得 BioNTech 股票在所有公司中排名前 1%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid<blockquote>BioNTech 股票因盈利大幅上涨；公司着眼于新冠疫情之外</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid<blockquote>BioNTech 股票因盈利大幅上涨；公司着眼于新冠疫情之外</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time smaller\">2021-08-09 21:15</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.</p><p><blockquote>BioNTech 股价周一大幅上涨，此前这家新冠疫苗制造商公布第二季度销售额为 62.4 亿美元，调整后每股利润为 12.67 美元。</blockquote></p><p> Analysts polled by FactSet expected <b>BioNTech</b> to earn $8.87 per share on $3.83 billion in sales.</p><p><blockquote>FactSet 调查的分析师预计<b>生物技术</b>销售额为 38.3 亿美元，每股收益为 8.87 美元。</blockquote></p><p> In the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.</p><p><blockquote>去年同期，BioNTech 每股亏损 45 美分，收入为 4900 万美元。</blockquote></p><p> BioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the <b>Pfizer</b> partner to earn $33.12 a share on $14.68 billion in sales.</p><p><blockquote>BioNTech 没有提供全年销售和盈利指引。该公司指出，已达成协议，将在 2021 年交付 22 亿剂新冠疫苗，目前正在研发多种抗癌药物。分析师呼吁<b>辉瑞</b>partner 的销售额为 146.8 亿美元，每股收益为 33.12 美元。</blockquote></p><p> In premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.</p><p><blockquote>在今天股市盘前交易中，BioNTech 股价上涨 5%，接近 408.50 点。根据 IBD Digital 的数据，该股的相对强弱评级为 99。就 12 个月的业绩而言，这使得 BioNTech 股票在所有公司中排名前 1%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158238441","content_text":"BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.\nAnalysts polled by FactSet expected BioNTech to earn $8.87 per share on $3.83 billion in sales.\nIn the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.\nBioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the Pfizer partner to earn $33.12 a share on $14.68 billion in sales.\nIn premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.","news_type":1,"symbols_score_info":{"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":2756,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802534082,"gmtCreate":1627787044146,"gmtModify":1631889789579,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"title":"","htmlText":"Like &amp; comment, please………….👆🏻🙏🏻","listText":"Like &amp; comment, please………….👆🏻🙏🏻","text":"Like & comment, please………….👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/802534082","repostId":"2155001152","repostType":4,"isVote":1,"tweetType":1,"viewCount":2350,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802379206,"gmtCreate":1627725322505,"gmtModify":1631889789594,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"title":"","htmlText":"Please like ……….………………….👆🏻🙏🏻","listText":"Please like ……….………………….👆🏻🙏🏻","text":"Please like ……….………………….👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/802379206","repostId":"2155001152","repostType":4,"isVote":1,"tweetType":1,"viewCount":3015,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":375007723,"gmtCreate":1619252337662,"gmtModify":1631893519229,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"title":"","htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/375007723","repostId":"1180713929","repostType":4,"repost":{"id":"1180713929","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1619191972,"share":"https://www.laohunote.com/m/news/1180713929?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:32","market":"us","language":"en","title":"Why AMD Stock Popped After Intel's Earnings Beat<blockquote>为什么英特尔盈利超出预期后 AMD 股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1180713929","media":"Tiger Newspress","summary":"Here's a hint: It's not because Intel reported great news.What happenedShares of rising Intel (NASDA","content":"<p>Here's a hint: It's not because Intel reported great news.</p><p><blockquote>这里有一个提示：这并不是因为英特尔报道了好消息。</blockquote></p><p><b>What happened</b></p><p><blockquote><b>发生了什么事</b></blockquote></p><p>Shares of rising&nbsp;<b>Intel</b>&nbsp;(NASDAQ:INTC)&nbsp;rival and fellow&nbsp;semiconductors&nbsp;giant&nbsp;<b>Advanced Micro Devices</b>&nbsp;(NASDAQ:AMD)&nbsp;popped in early trading on the Nasdaq Friday, the first day afterIntel's disappointing Q1 2021 earnings report. AMD's shares were up 4.5% as of 11:30 a.m. EDT.</p><p><blockquote>瑞星股份<b>英特尔</b>（纳斯达克股票代码：INTC）竞争对手和同行半导体巨头<b>先进微器件</b>（纳斯达克股票代码：AMD）周五在纳斯达克早盘交易中大幅上涨，这是英特尔令人失望的 2021 年第一季度收益报告发布后的第一天。截至美国东部时间上午 11:30，AMD 股价上涨 4.5%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/368e9bc79febd0164dab4a88ffd13c42\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/cf04377bf945cfdaa9a52157bb5560f7\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p><b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p>Intel, if you haven't heard, actually&nbsp;beat&nbsp;on its Q1 earnings. Despite sales declining 1% year over year, the company managed to report a pro forma profit of $1.39 per share, which was ahead of analyst expectations.</p><p><blockquote>如果你还没听说过的话，英特尔第一季度的盈利实际上超出了预期。尽管销售额同比下降 1%，但该公司仍实现了每股 1.39 美元的备考利润，超出了分析师的预期。</blockquote></p><p>Regardless, Intel reported a steep 540 basis point decline in its gross margin to 55.2%, and it saw its operating margin cut nearly in half as the company spent heavily to race to catch up to its rivals in advanced computer chips. Analysts at Citigroup commented yesterday that Intel stock appears to be close to its peak valuation and is likely to decline as investors acclimate to the new environment in which Intel is losing, not gaining, market share.</p><p><blockquote>无论如何，英特尔报告其毛利率大幅下降 540 个基点至 55.2%，并且由于该公司斥巨资在先进计算机芯片领域追赶竞争对手，其营业利润率下降了近一半。花旗集团分析师昨日评论称，英特尔股价似乎已接近峰值估值，随着投资者适应英特尔市场份额正在失去而不是增加的新环境，英特尔股价可能会下跌。</blockquote></p><p>And the reason this is good news for&nbsp;AMD&nbsp;is that, according to Citi at least, it's AMD that's taking that market share away from Intel.</p><p><blockquote>这对 AMD 来说是个好消息的原因是，至少根据花旗的说法，是 AMD 从英特尔手中夺走了市场份额。</blockquote></p><p><b>Now what</b></p><p><blockquote><b>现在呢</b></blockquote></p><p>So what's an investor to do with all this information?</p><p><blockquote>那么投资者该如何处理所有这些信息呢？</blockquote></p><p>At a valuation of just 13.6 times trailing earnings, Intel stock certainly looks like a relative bargain when compared with AMD stock, which trades at 38.4 times earnings. But AMD has acash-rich balance sheet, versus Intel that's carrying $13.5 billion in net debt. And analysts see Intel's earnings growing only 10% annually over the next five years, while AMD is pegged for 29.5% annualized earnings growth, according toS&amp;P Global Market Intelligencedata.</p><p><blockquote>英特尔股票的估值仅为历史市盈率的 13.6 倍，与市盈率为 38.4 倍的 AMD 股票相比，看起来确实相对便宜。但 AMD 的资产负债表现金充裕，而英特尔的净债务为 135 亿美元。根据 toS&amp;P Global Market Intelligencedata，分析师预计英特尔未来五年的盈利年增长率仅为 10%，而 AMD 的年化盈利增长率为 29.5%。</blockquote></p><p>Intel may&nbsp;look&nbsp;like&nbsp;a value stockright now, but it's AMD that's gotall the momentum.</p><p><blockquote>英特尔现在可能看起来像是一只价值股，但 AMD 正在推动这一势头。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why AMD Stock Popped After Intel's Earnings Beat<blockquote>为什么英特尔盈利超出预期后 AMD 股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy AMD Stock Popped After Intel's Earnings Beat<blockquote>为什么英特尔盈利超出预期后 AMD 股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-04-23 23:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Here's a hint: It's not because Intel reported great news.</p><p><blockquote>这里有一个提示：这并不是因为英特尔报道了好消息。</blockquote></p><p><b>What happened</b></p><p><blockquote><b>发生了什么事</b></blockquote></p><p>Shares of rising&nbsp;<b>Intel</b>&nbsp;(NASDAQ:INTC)&nbsp;rival and fellow&nbsp;semiconductors&nbsp;giant&nbsp;<b>Advanced Micro Devices</b>&nbsp;(NASDAQ:AMD)&nbsp;popped in early trading on the Nasdaq Friday, the first day afterIntel's disappointing Q1 2021 earnings report. AMD's shares were up 4.5% as of 11:30 a.m. EDT.</p><p><blockquote>瑞星股份<b>英特尔</b>（纳斯达克股票代码：INTC）竞争对手和同行半导体巨头<b>先进微器件</b>（纳斯达克股票代码：AMD）周五在纳斯达克早盘交易中大幅上涨，这是英特尔令人失望的 2021 年第一季度收益报告发布后的第一天。截至美国东部时间上午 11:30，AMD 股价上涨 4.5%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/368e9bc79febd0164dab4a88ffd13c42\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/cf04377bf945cfdaa9a52157bb5560f7\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p><b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p>Intel, if you haven't heard, actually&nbsp;beat&nbsp;on its Q1 earnings. Despite sales declining 1% year over year, the company managed to report a pro forma profit of $1.39 per share, which was ahead of analyst expectations.</p><p><blockquote>如果你还没听说过的话，英特尔第一季度的盈利实际上超出了预期。尽管销售额同比下降 1%，但该公司仍实现了每股 1.39 美元的备考利润，超出了分析师的预期。</blockquote></p><p>Regardless, Intel reported a steep 540 basis point decline in its gross margin to 55.2%, and it saw its operating margin cut nearly in half as the company spent heavily to race to catch up to its rivals in advanced computer chips. Analysts at Citigroup commented yesterday that Intel stock appears to be close to its peak valuation and is likely to decline as investors acclimate to the new environment in which Intel is losing, not gaining, market share.</p><p><blockquote>无论如何，英特尔报告其毛利率大幅下降 540 个基点至 55.2%，并且由于该公司斥巨资在先进计算机芯片领域追赶竞争对手，其营业利润率下降了近一半。花旗集团分析师昨日评论称，英特尔股价似乎已接近峰值估值，随着投资者适应英特尔市场份额正在失去而不是增加的新环境，英特尔股价可能会下跌。</blockquote></p><p>And the reason this is good news for&nbsp;AMD&nbsp;is that, according to Citi at least, it's AMD that's taking that market share away from Intel.</p><p><blockquote>这对 AMD 来说是个好消息的原因是，至少根据花旗的说法，是 AMD 从英特尔手中夺走了市场份额。</blockquote></p><p><b>Now what</b></p><p><blockquote><b>现在呢</b></blockquote></p><p>So what's an investor to do with all this information?</p><p><blockquote>那么投资者该如何处理所有这些信息呢？</blockquote></p><p>At a valuation of just 13.6 times trailing earnings, Intel stock certainly looks like a relative bargain when compared with AMD stock, which trades at 38.4 times earnings. But AMD has acash-rich balance sheet, versus Intel that's carrying $13.5 billion in net debt. And analysts see Intel's earnings growing only 10% annually over the next five years, while AMD is pegged for 29.5% annualized earnings growth, according toS&amp;P Global Market Intelligencedata.</p><p><blockquote>英特尔股票的估值仅为历史市盈率的 13.6 倍，与市盈率为 38.4 倍的 AMD 股票相比，看起来确实相对便宜。但 AMD 的资产负债表现金充裕，而英特尔的净债务为 135 亿美元。根据 toS&amp;P Global Market Intelligencedata，分析师预计英特尔未来五年的盈利年增长率仅为 10%，而 AMD 的年化盈利增长率为 29.5%。</blockquote></p><p>Intel may&nbsp;look&nbsp;like&nbsp;a value stockright now, but it's AMD that's gotall the momentum.</p><p><blockquote>英特尔现在可能看起来像是一只价值股，但 AMD 正在推动这一势头。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMD":"美国超微公司","INTC":"英特尔"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180713929","content_text":"Here's a hint: It's not because Intel reported great news.What happenedShares of rising Intel (NASDAQ:INTC) rival and fellow semiconductors giant Advanced Micro Devices (NASDAQ:AMD) popped in early trading on the Nasdaq Friday, the first day afterIntel's disappointing Q1 2021 earnings report. AMD's shares were up 4.5% as of 11:30 a.m. EDT.So whatIntel, if you haven't heard, actually beat on its Q1 earnings. Despite sales declining 1% year over year, the company managed to report a pro forma profit of $1.39 per share, which was ahead of analyst expectations.Regardless, Intel reported a steep 540 basis point decline in its gross margin to 55.2%, and it saw its operating margin cut nearly in half as the company spent heavily to race to catch up to its rivals in advanced computer chips. Analysts at Citigroup commented yesterday that Intel stock appears to be close to its peak valuation and is likely to decline as investors acclimate to the new environment in which Intel is losing, not gaining, market share.And the reason this is good news for AMD is that, according to Citi at least, it's AMD that's taking that market share away from Intel.Now whatSo what's an investor to do with all this information?At a valuation of just 13.6 times trailing earnings, Intel stock certainly looks like a relative bargain when compared with AMD stock, which trades at 38.4 times earnings. But AMD has acash-rich balance sheet, versus Intel that's carrying $13.5 billion in net debt. And analysts see Intel's earnings growing only 10% annually over the next five years, while AMD is pegged for 29.5% annualized earnings growth, according toS&P Global Market Intelligencedata.Intel may look like a value stockright now, but it's AMD that's gotall the momentum.","news_type":1,"symbols_score_info":{"AMD":0.9,"INTC":0.9}},"isVote":1,"tweetType":1,"viewCount":572,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891650118,"gmtCreate":1628388100434,"gmtModify":1631889789559,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"title":"","htmlText":"Like &amp; comment, please………👆🏻🙏🏻","listText":"Like &amp; comment, please………👆🏻🙏🏻","text":"Like & comment, please………👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/891650118","repostId":"1180529438","repostType":4,"repost":{"id":"1180529438","kind":"news","pubTimestamp":1628386129,"share":"https://www.laohunote.com/m/news/1180529438?lang=zh_CN&edition=full","pubTime":"2021-08-08 09:28","market":"us","language":"en","title":"SEC Moves First DeFi Unregistered Securities Lawsuit<blockquote>SEC 提起首例 DeFi 未注册证券诉讼</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1180529438","media":"Benzinga","summary":"The United States Securities and Exchange Commission  sued the organization responsible for the development of a decentralized finance  protocol over activities involved with the project for the first time.What Happened: According to a Friday SEC announcement, the agency has sued Cayman Islands-based Blockchain Credit Partners and two of its top executives over allegedly selling unregistered securities through its DeFi Money Market platform from February 2020 to February 2021. The firm purported","content":"<p><div> The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project ...</p><p><blockquote><div>美国证券交易委员会（SEC）就该项目涉及的活动起诉了负责开发去中心化金融（DeFi）协议的组织……</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">网页连接</a></blockquote></p><p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SEC Moves First DeFi Unregistered Securities Lawsuit<blockquote>SEC 提起首例 DeFi 未注册证券诉讼</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSEC Moves First DeFi Unregistered Securities Lawsuit<blockquote>SEC 提起首例 DeFi 未注册证券诉讼</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2021-08-08 09:28</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project ...</p><p><blockquote><div>美国证券交易委员会（SEC）就该项目涉及的活动起诉了负责开发去中心化金融（DeFi）协议的组织……</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">Benzinga</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc."},"source_url":"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180529438","content_text":"The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project for the first time.\nWhat Happened: According to a Friday SEC announcement, the agency has sued Cayman Islands-based Blockchain Credit Partners and two of its top executives over allegedly selling unregistered securities through its DeFi Money Market platform from February 2020 to February 2021. The firm purportedly sold over $30 million worth of two types of tokens that the SEC deemed to be securities that should have been registered as such.\nThe SEC notes that Blockchain Credit Partners founders Gregory Keough and Derek Acree will have to pay fines of $125,000 while the company itself also agreed to pay $12.8 million in disgorgement. The settlement does not indicate an admition or denial the accusations.\nNew Game, Old Rules?\nSEC Enforcement Director Gurbir Grewal explained that \"full and honest disclosure remains the cornerstone of our securities laws — no matter what technologies are used to offer and sell those securities.\" This comment makes it very clear that slapping the DeFi label on a project and hoping to avoid regulation this way works no better than calling it a \"utility token\" prevented falling under the SEC's scrutiny during 2017's initial coin offering craze.\nThe SEC is trying to send the clear rule that the new kind of financial organizations that operate on blockchains have to still play by the old rules that govern traditional finance. At the same time, market onlookers are not sure if the regulator is actually right.\nIn a way, it is a tour de force where the regulator wins every time it has a way to take enforcement action, but these new organizations potentially have a very real way to make enforcement impossible — or at the very least impractical. The only protection against enforcement by the SEC and other regulators is decentralization and the only reason why the SEC was able to act in this case is that a centralized organization such as Blockchain Credit Partners exists.\nWhat's Next:If no company exists and all that there is to a DeFi protocol is a set of smart contracts deployed on a blockchain by a group of anonymous developers scattered around the world there is very little that the SEC can do short of attacking the blockchain itself. This is where the decentralization of the underlying blockchain comes into play: will the regulators for instance be able to force Ethereum's (CRYPTO: ETH) core development team to write an update stopping such a project?\nIf the regulators would actually be able to force the blockchain's developers to write such an update, would node operators and miners or stakers adopt this software or would they refuse to? Such situations will be the real test of the decentralization and reliability of any blockchain that many are waiting to happen. Regulators are seeing power slipping away between their fingers like sand, and they are going to try to grab it.","news_type":1,"symbols_score_info":{"COIN":0.9}},"isVote":1,"tweetType":1,"viewCount":3096,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802510374,"gmtCreate":1627787223898,"gmtModify":1631889789570,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"title":"","htmlText":"Please like and comment 🙏🏻","listText":"Please like and comment 🙏🏻","text":"Please like and comment 🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/802510374","repostId":"1159296868","repostType":4,"isVote":1,"tweetType":1,"viewCount":2760,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":344773698,"gmtCreate":1618446449514,"gmtModify":1634292911898,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"title":"","htmlText":"It’s temporary 🦾","listText":"It’s temporary 🦾","text":"It’s temporary 🦾","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/344773698","repostId":"1189551384","repostType":4,"isVote":1,"tweetType":1,"viewCount":635,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":608534193,"gmtCreate":1638756985400,"gmtModify":1638756985492,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/608534193","repostId":"1125593879","repostType":4,"repost":{"id":"1125593879","kind":"news","pubTimestamp":1638756575,"share":"https://www.laohunote.com/m/news/1125593879?lang=zh_CN&edition=full","pubTime":"2021-12-06 10:09","market":"us","language":"en","title":"Why Moderna Is the Biggest Winner From COVID Boosters So Far<blockquote>为什么 Moderna 是迄今为止新冠疫苗的最大赢家</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125593879","media":"Motley Fool","summary":"It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authoriz","content":"<p>It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authorized boosters for the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) for certain groups. Around two and half months ago, the agency granted authorizations for boosters for Moderna's (NASDAQ:MRNA) and Johnson &amp; Johnson's (NYSE:JNJ) vaccines, with limitations for which individuals could receive the Moderna booster.</p><p><blockquote>距离美国已经过去了大约三个半月。美国食品药品监督管理局 (FDA) 批准辉瑞 (NYSE:PFE) 和 BioNTech (NASDAQ:BNTX) 为某些群体开发的 COVID-19 疫苗加强剂。大约两个半月前，该机构批准了 Moderna（纳斯达克股票代码：MRNA）和强生公司（纽约证券交易所股票代码：JNJ）疫苗的加强剂，但对个人可以接受 Moderna 加强剂的数量有限制。</blockquote></p><p> A little over two weeks ago, the FDA broadened its Emergency Use Authorization for the Pfizer-BioNTech and Moderna boosters to include all adults ages 18 and older. Overall, close to 42 million Americans have received booster shots.</p><p><blockquote>两个多星期前，FDA扩大了辉瑞-BioNTech和Moderna加强剂的紧急使用授权，将所有18岁及以上的成年人包括在内。总体而言，近 4200 万美国人接受了加强注射。</blockquote></p><p> Which vaccine maker is winning the battle of the boosters so far? It's still early, but Moderna appears to be ahead in several respects</p><p><blockquote>到目前为止，哪家疫苗制造商正在赢得加强剂之战？现在还为时尚早，但 Moderna 似乎在几个方面处于领先地位</blockquote></p><p> <b>Analyzing the data</b></p><p><blockquote><b>分析数据</b></blockquote></p><p> More booster doses of the Pfizer-BioNTech vaccine have been given than have been administered for the Moderna and J&amp;J boosters. Pfizer and BioNTech are clearly in the lead on this front.</p><p><blockquote>辉瑞-BioNTech疫苗的加强剂量超过了Moderna和J&amp;J加强剂。辉瑞和BioNTech显然在这方面处于领先地位。</blockquote></p><p> You'd expect that more people would have received the Pfizer-BioNTech booster. It's been available for many Americans (including those ages 65 and older) for a month longer than the other two vaccine types.</p><p><blockquote>你会期望更多的人会接受辉瑞-BioNTech加强剂。许多美国人（包括65岁及以上的人）的接种时间比其他两种疫苗多一个月。</blockquote></p><p> Also, many more individuals received the Pfizer-BioNTech vaccine initially than received the other two vaccines. A lot of those people chose to receive the booster of the same vaccine that they received for their primary series. The chart below shows how the different vaccines stack up against each other based on the fully vaccinated numbers.</p><p><blockquote>此外，最初接受辉瑞-BioNTech疫苗的人比接受其他两种疫苗的人多得多。这些人中的许多人选择接受与他们在主要系列中接受的相同疫苗的加强。下图显示了基于完全接种疫苗的数量，不同疫苗是如何相互对抗的。</blockquote></p><p> So why do I maintain that Moderna is the biggest winner with boosters so far and not Pfizer or BioNTech? There are three reasons.</p><p><blockquote>那么，为什么我坚持认为Moderna是迄今为止最大的助推器赢家，而不是辉瑞或BioNTech呢？原因有三个。</blockquote></p><p> First, from a financial standpoint, Moderna's 18 million booster doses made it more money than Pfizer or BioNTech made from their 23.3 million or so booster doses. Moderna doesn't have to split its profits as Pfizer and BioNTech do.</p><p><blockquote>首先，从财务角度来看，Moderna 的 1800 万剂加强剂比辉瑞或 BioNTech 的 2330 万剂左右加强剂赚的钱还要多。Moderna 不必像辉瑞和 BioNTech 那样分配利润。</blockquote></p><p> Second, Moderna is gaining more traction with boosters than Pfizer-BioNTech or J&amp;J are. A little over 25% of the number of fully vaccinated individuals receiving the primary series of the Moderna vaccine have received Moderna boosters. The ratio is 21.3% for Pfizer-BioNTech.</p><p><blockquote>其次，与辉瑞-BioNTech或强生相比，Moderna在加强剂方面获得了更多的牵引力。接受Moderna疫苗初级系列的完全接种疫苗的个体中，略高于25%的人接受了Moderna加强剂。辉瑞-BioNTech的这一比例为21.3%。</blockquote></p><p> Third, with the FDA allowing mix-and-match boosters, more people appear to be switching from another vaccine to Moderna than they are to any other vaccine type. For those who initially received the J&amp;J vaccine, 42.5% so far have gone with the Moderna booster versus 31.2% for a Pfizer-BioNTech booster and only 26.2% for a J&amp;J booster.</p><p><blockquote>第三，随着FDA允许混合搭配加强剂，从另一种疫苗转向Moderna的人似乎比任何其他疫苗类型的人都多。对于那些最初接受J&amp;J疫苗的人来说，到目前为止，42.5%的人使用了Moderna加强剂，而31.2%的人使用了辉瑞-BioNTech加强剂，只有26.2%的人使用了J&amp;J加强剂。</blockquote></p><p> <b>Why is Moderna winning?</b></p><p><blockquote><b>为什么Moderna会赢？</b></blockquote></p><p> We don't know for sure why Moderna seems to be gaining momentum. However, I have a theory for why it could be happening.</p><p><blockquote>我们不确定为什么 Moderna 似乎势头强劲。然而，我有一个理论来解释为什么会发生这种情况。</blockquote></p><p> My hunch is that many Americans have heard that Moderna's efficacy against the delta variant is higher than the efficacy of the Pfizer-BioNTech and Johnson &amp; Johnson vaccines. The initial efficacy of the single-shot J&amp;J vaccine was well below its two messenger RNA vaccine rivals. And the efficacy of the Pfizer-BioNTech vaccine appears to have waned more than the Moderna vaccine has with the rise of the delta variant.</p><p><blockquote>我的预感是，许多美国人都听说过 Moderna 对德尔塔变异毒株的效力高于辉瑞-BioNTech 和强生疫苗的效力。强生单针疫苗的初始效力远低于其两种信使RNA疫苗竞争对手。随着德尔塔变异毒株的上升，辉瑞-BioNTech疫苗的效力似乎比Moderna疫苗减弱得多。</blockquote></p><p> I suspect that preliminary data showing that a mix-and-match combination of the Pfizer-BioNTech primary series and a Moderna booster provides a higher efficacy could also be making a difference to some extent. Singapore's minister of health even recently recommended that citizens in the country who initially received the Pfizer-BioNTech vaccine get the Moderna booster.</p><p><blockquote>我怀疑，初步数据显示辉瑞-BioNTech初级系列和Moderna加强剂的混合搭配组合提供了更高的功效，这也可能在某种程度上产生影响。新加坡卫生部长最近甚至建议该国最初接种辉瑞-BioNTech疫苗的公民接种Moderna加强剂。</blockquote></p><p> <b>What really matters</b></p><p><blockquote><b>真正重要的是什么</b></blockquote></p><p> Don't expect Moderna's relative outperformance in boosters to do much for the vaccine stock. Many investors aren't paying attention to the data. And the U.S. has already purchased enough doses from Moderna to meet the demand, including boosters.</p><p><blockquote>不要指望 Moderna 在加强剂方面的相对优异表现会对疫苗库存产生太大影响。许多投资者并没有关注这些数据。美国已经从 Moderna 购买了足够的剂量来满足需求，包括加强剂。</blockquote></p><p> What really matters for Moderna is how strong the longer-term demand will be for its COVID-19 vaccine. The company's efforts fighting the new omicron variant could play a key role in shaping that demand. But the most important factors will be whether or not annual vaccines are required to prevent COVID-19 and, if so, what price Moderna will be able to charge.</p><p><blockquote>对 Moderna 来说真正重要的是对其 COVID-19 疫苗的长期需求有多强劲。该公司对抗新奥密克戎变种的努力可能会在塑造这一需求方面发挥关键作用。但最重要的因素将是是否需要每年接种疫苗来预防 COVID-19，如果是，Moderna 将能够收取什么价格。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Is the Biggest Winner From COVID Boosters So Far<blockquote>为什么 Moderna 是迄今为止新冠疫苗的最大赢家</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Is the Biggest Winner From COVID Boosters So Far<blockquote>为什么 Moderna 是迄今为止新冠疫苗的最大赢家</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-12-06 10:09</span>\n</p>\n</h4>\n</header>\n<article>\n<p>It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authorized boosters for the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) for certain groups. Around two and half months ago, the agency granted authorizations for boosters for Moderna's (NASDAQ:MRNA) and Johnson &amp; Johnson's (NYSE:JNJ) vaccines, with limitations for which individuals could receive the Moderna booster.</p><p><blockquote>距离美国已经过去了大约三个半月。美国食品药品监督管理局 (FDA) 批准辉瑞 (NYSE:PFE) 和 BioNTech (NASDAQ:BNTX) 为某些群体开发的 COVID-19 疫苗加强剂。大约两个半月前，该机构批准了 Moderna（纳斯达克股票代码：MRNA）和强生公司（纽约证券交易所股票代码：JNJ）疫苗的加强剂，但对个人可以接受 Moderna 加强剂的数量有限制。</blockquote></p><p> A little over two weeks ago, the FDA broadened its Emergency Use Authorization for the Pfizer-BioNTech and Moderna boosters to include all adults ages 18 and older. Overall, close to 42 million Americans have received booster shots.</p><p><blockquote>两个多星期前，FDA扩大了辉瑞-BioNTech和Moderna加强剂的紧急使用授权，将所有18岁及以上的成年人包括在内。总体而言，近 4200 万美国人接受了加强注射。</blockquote></p><p> Which vaccine maker is winning the battle of the boosters so far? It's still early, but Moderna appears to be ahead in several respects</p><p><blockquote>到目前为止，哪家疫苗制造商正在赢得加强剂之战？现在还为时尚早，但 Moderna 似乎在几个方面处于领先地位</blockquote></p><p> <b>Analyzing the data</b></p><p><blockquote><b>分析数据</b></blockquote></p><p> More booster doses of the Pfizer-BioNTech vaccine have been given than have been administered for the Moderna and J&amp;J boosters. Pfizer and BioNTech are clearly in the lead on this front.</p><p><blockquote>辉瑞-BioNTech疫苗的加强剂量超过了Moderna和J&amp;J加强剂。辉瑞和BioNTech显然在这方面处于领先地位。</blockquote></p><p> You'd expect that more people would have received the Pfizer-BioNTech booster. It's been available for many Americans (including those ages 65 and older) for a month longer than the other two vaccine types.</p><p><blockquote>你会期望更多的人会接受辉瑞-BioNTech加强剂。许多美国人（包括65岁及以上的人）的接种时间比其他两种疫苗多一个月。</blockquote></p><p> Also, many more individuals received the Pfizer-BioNTech vaccine initially than received the other two vaccines. A lot of those people chose to receive the booster of the same vaccine that they received for their primary series. The chart below shows how the different vaccines stack up against each other based on the fully vaccinated numbers.</p><p><blockquote>此外，最初接受辉瑞-BioNTech疫苗的人比接受其他两种疫苗的人多得多。这些人中的许多人选择接受与他们在主要系列中接受的相同疫苗的加强。下图显示了基于完全接种疫苗的数量，不同疫苗是如何相互对抗的。</blockquote></p><p> So why do I maintain that Moderna is the biggest winner with boosters so far and not Pfizer or BioNTech? There are three reasons.</p><p><blockquote>那么，为什么我坚持认为Moderna是迄今为止最大的助推器赢家，而不是辉瑞或BioNTech呢？原因有三个。</blockquote></p><p> First, from a financial standpoint, Moderna's 18 million booster doses made it more money than Pfizer or BioNTech made from their 23.3 million or so booster doses. Moderna doesn't have to split its profits as Pfizer and BioNTech do.</p><p><blockquote>首先，从财务角度来看，Moderna 的 1800 万剂加强剂比辉瑞或 BioNTech 的 2330 万剂左右加强剂赚的钱还要多。Moderna 不必像辉瑞和 BioNTech 那样分配利润。</blockquote></p><p> Second, Moderna is gaining more traction with boosters than Pfizer-BioNTech or J&amp;J are. A little over 25% of the number of fully vaccinated individuals receiving the primary series of the Moderna vaccine have received Moderna boosters. The ratio is 21.3% for Pfizer-BioNTech.</p><p><blockquote>其次，与辉瑞-BioNTech或强生相比，Moderna在加强剂方面获得了更多的牵引力。接受Moderna疫苗初级系列的完全接种疫苗的个体中，略高于25%的人接受了Moderna加强剂。辉瑞-BioNTech的这一比例为21.3%。</blockquote></p><p> Third, with the FDA allowing mix-and-match boosters, more people appear to be switching from another vaccine to Moderna than they are to any other vaccine type. For those who initially received the J&amp;J vaccine, 42.5% so far have gone with the Moderna booster versus 31.2% for a Pfizer-BioNTech booster and only 26.2% for a J&amp;J booster.</p><p><blockquote>第三，随着FDA允许混合搭配加强剂，从另一种疫苗转向Moderna的人似乎比任何其他疫苗类型的人都多。对于那些最初接受J&amp;J疫苗的人来说，到目前为止，42.5%的人使用了Moderna加强剂，而31.2%的人使用了辉瑞-BioNTech加强剂，只有26.2%的人使用了J&amp;J加强剂。</blockquote></p><p> <b>Why is Moderna winning?</b></p><p><blockquote><b>为什么Moderna会赢？</b></blockquote></p><p> We don't know for sure why Moderna seems to be gaining momentum. However, I have a theory for why it could be happening.</p><p><blockquote>我们不确定为什么 Moderna 似乎势头强劲。然而，我有一个理论来解释为什么会发生这种情况。</blockquote></p><p> My hunch is that many Americans have heard that Moderna's efficacy against the delta variant is higher than the efficacy of the Pfizer-BioNTech and Johnson &amp; Johnson vaccines. The initial efficacy of the single-shot J&amp;J vaccine was well below its two messenger RNA vaccine rivals. And the efficacy of the Pfizer-BioNTech vaccine appears to have waned more than the Moderna vaccine has with the rise of the delta variant.</p><p><blockquote>我的预感是，许多美国人都听说过 Moderna 对德尔塔变异毒株的效力高于辉瑞-BioNTech 和强生疫苗的效力。强生单针疫苗的初始效力远低于其两种信使RNA疫苗竞争对手。随着德尔塔变异毒株的上升，辉瑞-BioNTech疫苗的效力似乎比Moderna疫苗减弱得多。</blockquote></p><p> I suspect that preliminary data showing that a mix-and-match combination of the Pfizer-BioNTech primary series and a Moderna booster provides a higher efficacy could also be making a difference to some extent. Singapore's minister of health even recently recommended that citizens in the country who initially received the Pfizer-BioNTech vaccine get the Moderna booster.</p><p><blockquote>我怀疑，初步数据显示辉瑞-BioNTech初级系列和Moderna加强剂的混合搭配组合提供了更高的功效，这也可能在某种程度上产生影响。新加坡卫生部长最近甚至建议该国最初接种辉瑞-BioNTech疫苗的公民接种Moderna加强剂。</blockquote></p><p> <b>What really matters</b></p><p><blockquote><b>真正重要的是什么</b></blockquote></p><p> Don't expect Moderna's relative outperformance in boosters to do much for the vaccine stock. Many investors aren't paying attention to the data. And the U.S. has already purchased enough doses from Moderna to meet the demand, including boosters.</p><p><blockquote>不要指望 Moderna 在加强剂方面的相对优异表现会对疫苗库存产生太大影响。许多投资者并没有关注这些数据。美国已经从 Moderna 购买了足够的剂量来满足需求，包括加强剂。</blockquote></p><p> What really matters for Moderna is how strong the longer-term demand will be for its COVID-19 vaccine. The company's efforts fighting the new omicron variant could play a key role in shaping that demand. But the most important factors will be whether or not annual vaccines are required to prevent COVID-19 and, if so, what price Moderna will be able to charge.</p><p><blockquote>对 Moderna 来说真正重要的是对其 COVID-19 疫苗的长期需求有多强劲。该公司对抗新奥密克戎变种的努力可能会在塑造这一需求方面发挥关键作用。但最重要的因素将是是否需要每年接种疫苗来预防 COVID-19，如果是，Moderna 将能够收取什么价格。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/12/05/why-moderna-is-the-biggest-winner-from-covid-boost/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/12/05/why-moderna-is-the-biggest-winner-from-covid-boost/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125593879","content_text":"It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authorized boosters for the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) for certain groups. Around two and half months ago, the agency granted authorizations for boosters for Moderna's (NASDAQ:MRNA) and Johnson & Johnson's (NYSE:JNJ) vaccines, with limitations for which individuals could receive the Moderna booster.\n\nA little over two weeks ago, the FDA broadened its Emergency Use Authorization for the Pfizer-BioNTech and Moderna boosters to include all adults ages 18 and older. Overall, close to 42 million Americans have received booster shots.\n\nWhich vaccine maker is winning the battle of the boosters so far? It's still early, but Moderna appears to be ahead in several respects\nAnalyzing the data\nMore booster doses of the Pfizer-BioNTech vaccine have been given than have been administered for the Moderna and J&J boosters. Pfizer and BioNTech are clearly in the lead on this front.\n\nYou'd expect that more people would have received the Pfizer-BioNTech booster. It's been available for many Americans (including those ages 65 and older) for a month longer than the other two vaccine types.\n\nAlso, many more individuals received the Pfizer-BioNTech vaccine initially than received the other two vaccines. A lot of those people chose to receive the booster of the same vaccine that they received for their primary series. The chart below shows how the different vaccines stack up against each other based on the fully vaccinated numbers.\n\nSo why do I maintain that Moderna is the biggest winner with boosters so far and not Pfizer or BioNTech? There are three reasons.\n\nFirst, from a financial standpoint, Moderna's 18 million booster doses made it more money than Pfizer or BioNTech made from their 23.3 million or so booster doses. Moderna doesn't have to split its profits as Pfizer and BioNTech do.\n\nSecond, Moderna is gaining more traction with boosters than Pfizer-BioNTech or J&J are. A little over 25% of the number of fully vaccinated individuals receiving the primary series of the Moderna vaccine have received Moderna boosters. The ratio is 21.3% for Pfizer-BioNTech.\n\nThird, with the FDA allowing mix-and-match boosters, more people appear to be switching from another vaccine to Moderna than they are to any other vaccine type. For those who initially received the J&J vaccine, 42.5% so far have gone with the Moderna booster versus 31.2% for a Pfizer-BioNTech booster and only 26.2% for a J&J booster.\n\nWhy is Moderna winning?\nWe don't know for sure why Moderna seems to be gaining momentum. However, I have a theory for why it could be happening.\n\nMy hunch is that many Americans have heard that Moderna's efficacy against the delta variant is higher than the efficacy of the Pfizer-BioNTech and Johnson & Johnson vaccines. The initial efficacy of the single-shot J&J vaccine was well below its two messenger RNA vaccine rivals. And the efficacy of the Pfizer-BioNTech vaccine appears to have waned more than the Moderna vaccine has with the rise of the delta variant.\n\nI suspect that preliminary data showing that a mix-and-match combination of the Pfizer-BioNTech primary series and a Moderna booster provides a higher efficacy could also be making a difference to some extent. Singapore's minister of health even recently recommended that citizens in the country who initially received the Pfizer-BioNTech vaccine get the Moderna booster.\n\nWhat really matters\nDon't expect Moderna's relative outperformance in boosters to do much for the vaccine stock. Many investors aren't paying attention to the data. And the U.S. has already purchased enough doses from Moderna to meet the demand, including boosters.\n\nWhat really matters for Moderna is how strong the longer-term demand will be for its COVID-19 vaccine. The company's efforts fighting the new omicron variant could play a key role in shaping that demand. But the most important factors will be whether or not annual vaccines are required to prevent COVID-19 and, if so, what price Moderna will be able to charge.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":3963,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":349868988,"gmtCreate":1617589262544,"gmtModify":1634297709423,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"title":"","htmlText":"[得意]&nbsp;[财迷]&nbsp;[笑哭]&nbsp;","listText":"[得意]&nbsp;[财迷]&nbsp;[笑哭]&nbsp;","text":"[得意] [财迷] [笑哭]","images":[{"img":"https://static.tigerbbs.com/dec358618f34345ab53891ca61fd409a","width":"1125","height":"1107"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/349868988","isVote":1,"tweetType":1,"viewCount":1833,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"lives":[]}